文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

间充质干细胞来源的细胞外囊泡减轻失血性休克与创伤诱导的肺血管通透性和肺损伤

Mesenchymal stem cell-derived extracellular vesicles attenuate pulmonary vascular permeability and lung injury induced by hemorrhagic shock and trauma.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论小鼠失血性休克模型中,静脉输注人间充质干细胞来源的细胞外囊泡与间充质干细胞均可显著降低失血性休克诱导的肺血管通透性。

该研究在小鼠固定压力失血性休克模型中,比较静脉给予间充质干细胞(MSCs)、MSC来源的细胞外囊泡(MSC EVs)或生理盐水对肺血管内皮通透性的影响。结果显示,失血性休克诱导的肺血管通透性在MSC与MSC EV输注组均显著降低,肺组织磷酸化蛋白谱显示细胞骨架重排与血管通透性调控相关蛋白及通路差异激活,治疗组肺组织细胞骨架GTP酶RhoA激活降低。体外实验中,人肺微血管细胞经凝血酶诱导后,MSC条件培养基(MSC CM)而非MSC EVs可阻止内皮细胞通透性增加。作者结论认为MSC EVs可能作为新型「无干细胞」疗法用于治疗失血性休克诱导的肺损伤。

要点

  • 小鼠固定压力失血性休克模型中,静脉输注MSC EVs与MSCs均显著降低失血性休克诱导的肺血管通透性。
  • 肺组织磷酸化蛋白谱显示MSCs与MSC EVs差异激活细胞骨架重排及血管通透性调控相关蛋白与通路。
  • 治疗组肺组织细胞骨架GTP酶RhoA激活降低。
  • 体外人肺微血管细胞中,MSC条件培养基(MSC CM)而非MSC EVs可阻止凝血酶诱导的内皮细胞通透性增加。
  • 作者认为MSC EVs可能作为新型「无干细胞」疗法用于治疗失血性休克诱导的肺损伤。

适用人群与场景

  • 小鼠固定压力失血性休克模型,用于研究休克、休克+MSCs及休克+MSC EVs对肺血管内皮通透性的影响。
  • 体外实验使用人肺微血管细胞评估连接完整性。

处置流程与药物剂量

  • MSC EVs由人骨髓来源MSCs经超速离心分离获得。
  • 小鼠经静脉给予MSCs、MSC EVs或生理盐水。

研究设计与关键结果

  • 研究类型为动物实验(小鼠固定压力失血性休克模型)及体外细胞实验。
  • 失血性休克诱导的肺血管通透性在MSC输注与MSC EV输注后均显著降低。
  • 肺组织磷酸化蛋白谱显示MSCs与MSC EVs差异激活细胞骨架重排及血管通透性调控相关蛋白与通路。
  • 治疗组肺组织细胞骨架GTP酶RhoA激活降低。
  • 体外人肺微血管细胞中,MSC条件培养基(MSC CM)而非MSC EVs可阻止凝血酶诱导的内皮细胞通透性增加(经电阻抗传感系统及VE-钙黏蛋白与肌动蛋白免疫细胞化学检测)。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠失血性休克模型)及体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为MSC EVs可能作为新型「无干细胞」疗法用于治疗失血性休克诱导的肺损伤。
  • 原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Mesenchymal stem cells (MSCs) have been shown to mitigate vascular permeability in hemorrhagic shock (HS) and trauma-induced brain and lung injury. Mechanistically, paracrine factors secreted from MSCs have been identified that can recapitulate many of the potent biologic effects of MSCs in animal models of disease. Interestingly, MSC-derived extracellular vesicles (EVs), contain many of these key soluble factors, and have therapeutic potential independent of the parent cells. In this study we sought to determine whether MSC-derived EVs (MSC EVs) could recapitulate the beneficial therapeutic effects of MSCs on lung vascular permeability induced by HS in mice.

METHODS: Mesenchymal stem cell EVs were isolated from human bone marrow-derived MSCs by ultracentrifugation. A mouse model of fixed pressure HS was used to study the effects of shock, shock + MSCs and shock + MSC EVs on lung vascular endothelial permeability. Mice were administered MSCs, MSC EVs, or saline IV. Lung tissue was harvested and assayed for permeability, RhoA/Rac1 activation, and for differential phosphoprotein expression. In vitro, human lung microvascular cells junctional integrity was evaluated by immunocytochemistry and endothelial cell impedance assays.

RESULTS: Hemorrhagic shock-induced lung vascular permeability was significantly decreased by both MSC and MSC EV infusion. Phosphoprotein profiling of lung tissue revealed differential activation of proteins and pathways related to cytoskeletal rearrangement and regulation of vascular permeability by MSCs and MSC EVs. Lung tissue from treatment groups demonstrated decreased activation of the cytoskeletal GTPase RhoA. In vitro, human lung microvascular cells, MSC CM but not MSC-EVs prevented thrombin-induced endothelial cell permeability as measured by electrical cell-substrate impedance sensing system and immunocytochemistry of VE-cadherin and actin.

CONCLUSION: Mesenchymal stem cells and MSC EVs modulate cytoskeletal signaling and attenuate lung vascular permeability after HS. Mesenchymal stem cell EVs may potentially be used as a novel "stem cell free" therapeutic to treat HS-induced lung injury.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Potter DR, Miyazawa BY, Gibb SL, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate pulmonary vascular permeability and lung injury induced by hemorrhagic shock and trauma. J Trauma Acute Care Surg. 2018. PMID: 29251710. doi:10.1097/TA.0000000000001744

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。